Source: Υπουργείο Υγείας (CY) Revision Year: 2020 Publisher: Remedica Ltd, Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus
Ermycin film-coated tablets are indicated in adults and children aged over 8 years for the treatment of infections caused by erythromycin-sensitive organisms. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
For mild to moderate infections 1-2 g daily in divided doses. Up to 4g daily in severe infections.
No special dosage recommendations.
Ermycin fc tablets are not recommended for use in children aged under 8 years. For younger children, infants and babies, Ermyced, erythromycin ethylsuccinate suspensions, are normally recommended.
Erythromycin should be used with caution in patients with impaired hepatic function (see sections 4.4 & 5.2).
For Oral administration.
Optimal serum levels of erythromycin are reached when erythromycin stearate is taken in the fasting state or immediately before meals.
Diarrhoea, severe nausea, vomiting and hearing loss.
Gastric lavage, general supportive measures.
5 years.
Store below 25°C, protected from light and moisture.
Ermycin 250 mg film-coated tablets:
PVC/Aluminium blisters. Pack sizes of 20, 100 and 1000 film-coated tablets.
PP containers with PE closure. Pack size of 1000 film-coated tablets.
Ermycin 500 mg film-coated tablets:
PVC/Aluminium blisters. Pack sizes of 12, 20, 100 and 1000 film-coated tablets.
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
